TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00686127
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 patch was applied topically to the affected site(s) for 12 hours each day.
Study: NCT00220363
Drug: SPM 907
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01046812
Drug: Caphosol
Normalized name: Caphosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caphosol 2-4 times daily oral rinse for two weeks duration minimum up to one month.
Study: NCT01552057
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken orally once every day for 15 weeks
Study: NCT01451593
Drug: Phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin will be loaded using at total dose of 15mg/kg (rounded to the nearest 100mg) divided into three equal doses given once daily for 3 days.This will be followed by a daily maintenance dose of 4mg/kg once a day (rounded up to the nearest 50mg, with a maximum dose of 300mg)for 13 weeks.Phenytoin levels will be taken at 1 and 3 months.
Study: NCT01451593
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo identical in appearance to active IMP (phenytoin)
Study: NCT02119715
Drug: Pegylated rhG-CSF 100μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of 2 to 4 chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy).
Study: NCT02119715
Drug: Pegylated rhG-CSF:150 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were administered pegylated rhG-CSF 150 ug/kg once at the 3rd day of 2 to 4 chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy).
Study: NCT02119715
Drug: rhG-CSF 5 μg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were administered rhG-CSF 5 ug/kg daily during chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy) until (1)continuous injection for 14 days (2)two successive ANC counts exceed 5.0×109/L（3）ANC counts exceed 15×109/L at anytime.
Study: NCT01784887
Drug: Procellera
Approvals — FDA: no, EMA: no, PMDA: no
Description: PROCELLERA TM is an FDA-cleared bioelectrical dressing delivered in a sterile, single layer sheet consisting of a flexible polyester fabric layer containing silver and zinc, which are held in position on the polyester with a biocompatible binder.
Study: NCT03115996
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT02582996
Drug: Acetaminophen+Caffeine+Dihydroergotamine+Metoclopramide.
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subject must manage 02 tablets of Cefalium right after a moderate to severe migraine.
Study: NCT02582996
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subject must manage 02 tablets of Tylenol right after a moderate to severe migraine.
Study: NCT00358657
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00460382
Drug: Optimized background regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRTIs and or enfuvirtide (investigator choice)
Study: NCT00928070
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo sham 4 mg and 8 mg
Study: NCT01849926
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01381055
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with cutaneous leishmaniasis treated with pentavalent antimony/metilglucamine 20mg/kg/day during 20 days and placebo pills three times a day during 20 days.
Study: NCT02752828
Drug: Oral anti-diabetic drugs
Normalized name: Diabetic Tussin EX Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT04807894
Drug: Vaginal Cream with Applicator
Normalized name: Amino-Cerv, vaginal cream with applicator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal testosterone 300-μg dose will be compounded with 13.5 mg of testosterone propionate in 0.45 mL of polysorbate National Formulary liquid and sufficient emollient cream base to make 45 g total. A calibrated vaginal applicator will be supplied to measure out doses of 1 g each. All study medications will be compounded by a single pharmacy so as to avoid variation in compounding between pharmacies and allow for control of compounding. Randomization will be conducted by the compounding pharmacy to allow for double-blinding of patients and clinicians.
Study: NCT04472728
Drug: BIO101
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIO101 capsules
Study: NCT04472728
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules
Study: NCT00640094
Drug: melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive a total intravenous melatonin dose of 12 mg + intracoronary melatonin dose of 2 mg. The intravenous dose will be distributed in a volume of 50 ml of a isotonic and sterile solution and administered by intravenous infusion during 60 minutes. The intracoronary dose will be distributed in a volume of 10 ml of a isotonic and sterile solution and administered as a bolus.
Study: NCT02786901
Drug: Vehicle Gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel
Study: NCT02013544
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02013544
Drug: Prasterone (DHEA)
Normalized name: prasterone (DHEA)
DrugBank: Prasterone sulfate (DB05804)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02183714
Drug: Songha Night ®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02183714
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00673595
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The pharmacy will prepare tablets that match the varenicline tablets. The tablets should be taken orally after food intake with 200 ml of water.
Study: NCT00733525
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg/day of fluoxetine, which can be incrementally increased to 80 mg/day
Study: NCT01748799
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants received the same interventions (Fixed or Self-Titrated Placebo), just in different sequences.
Study: NCT00516919
Drug: Xenical + behavioral intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg TID; Behavioral weight loss in Spanish
Study: NCT02494180
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: arm A receiving iv fentanyl
Study: NCT01955616
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05019586
Drug: levofloxacin, amoxicillin, clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy of Helicobacter pylori including two antibiotics and a proton inhibitor for 10 days
Study: NCT02276495
Drug: Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mLs of a solution containing:~Ropivacaine 2 mg/mL (49.25 mL) + Epinephrine 1 mg/mL (0.5 mL) + Ketorolac 30mg/mL (1mL) + Clonidine 100 mcg/mL (0.8 mL) + 0.9% Normal saline (48.45 mL)
Study: NCT00682656
Drug: Glucantime®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15mg Sb+5/Kg/day, during 20 days. Maximum dose:15ml/day
Study: NCT00682656
Drug: Zithromax ®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zithromax ®/ Pfizer, 500 mg - 1x day, during 20 days
Study: NCT00476190
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction: Intravenously on days 4 and 5. Consolidation 1A: Intravenously on day 1. CNS Therapy: Intravenously on day 1. Consolidation II: Intravenously day 1 of each cycle.
Study: NCT00476190
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction: Intravenously on day 6 and intrathecally on day 29 or 32. Consolidation IA: Intravenously on day 1 and intrathecally on Day 1 (prior to IV).~Consolidation IB: Intrathecally on day 1. CNS Therapy: Intrathecally 4 times over 2 weeks. Consolidation: Intrathecally once every 18 weeks. Continuation: Intravenously weekly and intrathecally every 18 weeks.
Study: NCT00476190
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Consolidation IB: Intravenously on day 1
Study: NCT00476190
Drug: Hydrocortisone Sodium Succinate
Normalized name: Hydrocortisone Sodium Succinate
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction: Intrathecally on day 15 or 18. CNS Therapy: Intrathecally 4 times over 2 weeks. Consolidation II: Intrathecally once every 18 weeks. Continuation: Intrathecally every 18 weeks.
Study: NCT00476190
Drug: E. coli Asparaginase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscularly Day 7 of Induction.
Study: NCT04183166
Drug: TG4050
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections weekly for the first 6 weeks and then every 3 weeks
Study: NCT01166165
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 placebo tablets daily for 20 weeks
Study: NCT00885079
Drug: OPC-12759 Ophthalmic suspension
Normalized name: Opcon-A Ophthalmic Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC-12759 Ophthalmic suspension 2%
Study: NCT00850746
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT00312455
Drug: Pro-eicosapentaenoic acid (EPA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg 5x/day
Study: NCT00312455
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 capsules/day
Study: NCT01082484
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
Study: NCT01272583
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, once daily for six weeks
Study: NCT00709202
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03512236
Drug: BC Pram Ins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of BC Pram Ins
Study: NCT03512236
Drug: Symlin® and Humulin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of pramlintide and human insulin
Study: NCT03512236
Drug: Humalog®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of lispro
Study: NCT03512236
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 0.9% NaCl
Study: NCT00646659
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02670395
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution will be administered orally.
Study: NCT03862755
Drug: Chemoprophylaxis with Low Molecular Weight Heparin (LMWH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early chemoprophylaxis means low-molecular weight heparin (LMWH) 3075 IU (WHO Units) injection subcutaneously one time a day no later than 24 hours after surgery. Early ambulation means activity out of bed no later than 24 hours after surgery. According to different risk level, patients received different thromboprophylaxis strategies. Early ambulation alone was for patients at low risk (Caprini 0-4), early chemoprophylaxis plus early ambulation was for patients at moderate (Caprini 5-8) or high risk (Caprini ≥9).
Study: NCT03880877
Drug: Leucovorin and 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period)
Study: NCT04109066
Drug: anthracycline
Normalized name: Anthracycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on Specified days
Study: NCT04109066
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on Specified days
Study: NCT04109066
Drug: Endocrine Therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variable endocrine therapy of investigators choice
Study: NCT00138762
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00787111
Drug: Fluoxetine (prozac)
Normalized name: fluoxetine Oral Capsule [Prozac]
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Formulation: ODT
Study: NCT04363216
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascor® ascorbic acid 2-hour infusion daily (for 6 days), escalating dose (0.3g/kg, 0.6g/kg, 0.9g/kg).
Study: NCT02695940
Drug: LEO 124249 ointment 30 mg/g
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00709826
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo: 100 mg tablets, 400 mg/day
Study: NCT02368470
Drug: Standard triple therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and clarithromycin (Klaricid®, Abbot Korea Co. Ltd., Seoul, Korea) 500 mg twice daily for 7 days
Study: NCT03445702
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic metformin 1000mg
Study: NCT01941589
Drug: oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: maximal oral 5-ASA+/-topical 5-ASA+IV corticosteroids
Study: NCT01479348
Drug: [F-18]-5-FLUORO-2'-DEOXYCYTIDINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18FdCyd radiotracer
Study: NCT01479348
Drug: Tetrahydrouridine intravenous (IV)
Normalized name: (4R)-2'-Deoxy-2',2'-difluoro-3,4,5,6-tetrahydrouridine
DrugBank: Cedazuridine (DB15694)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total dose of THU = 350 mg/m\^2, IV
Study: NCT01420770
Drug: SAR302503
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:capsule~Route of administration: oral
Study: NCT03246529
Drug: BL-8040 1.25 mg/kg + G-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 2 subcutaneous (SC) injections of BL-8040 are anticipated during the study. Injections of G-CSF per standard of care
Study: NCT01284504
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg tablet oral
Study: NCT01781455
Drug: BBI503
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03041311
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV
Study: NCT03211013
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: single-dose administration of placebo nasal spray, complete computer-based tasks post-dose for approximately 1 hour
Study: NCT00166790
Drug: chemotherapy agents
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03049449
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 or 500 mg/m\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3
Study: NCT01073579
Drug: Sabril®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infantile Spasms (IS): Initiate therapy at 50 mg/kg/day twice daily increasing total daily dose per instructions to a maximum of 150 mg/kg/day.~Refractory Complex Partial Seizures (rCPS) in Adults: Initiate therapy at 500 mg twice daily, increasing total daily dose per instructions. The recommended dose is 1.5 grams twice daily.
Study: NCT00386841
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03093402
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will self-administer JBT-101 placebo by mouth (orally), at prescribed dose and frequency per protocol, Days 1-84. Administration of dose(s) should be at least 8 hours apart.
Study: NCT01636492
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose
Study: NCT02886702
Drug: TAZORAC® (tazarotene) Cream 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAZORAC® (tazarotene) Cream 0.05% to cover only the lesions with a thin film.
Study: NCT02886702
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle of the test product) to cover only the lesions with a thin film.
Study: NCT03633279
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: an equinitrogenous amount of lactoalbumin 2.1 grams, and equicaloric amount with 4.0 g saccharose and 3.0 g mannitol for a total of 33.6 kcal/packet.(one packet at 6pm and two at 9pm)
Study: NCT06056947
Drug: EVEGYN A
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVEGYN A: Fixed-dose combination of 600 mg fenticonazole nitrate + 1000 mg tinidazole + 100 mg lidocaine vaginal ovule Single dose, single administration (1x1)
Study: NCT06056947
Drug: EVEGYN B
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVEGYN B: Fixed-dose combination of 600 mg fenticonazole nitrate + 2000 mg tinidazole + 100 mg lidocaine vaginal ovule Single dose, single administration (1x1)
Study: NCT06056947
Drug: Gynomax® XL Vaginal Ovule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg tioconazole + 300 mg tinidazole + 100 mg lidocaine single dose / day, during three consecutive days (1x1 / 3 days)
Study: NCT00055640
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide IV over 30 minutes. Treatment repeats every 21 days for 3-8 courses.
Study: NCT00055640
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin IV over 5 minutes. Treatment repeats every 21 days for 3-8 courses.
Study: NCT00000402
Drug: Calcium
Normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01597947
Drug: ACHN-975
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous single dose
Study: NCT01597947
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous single dose
Study: NCT02509559
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration of one placebo capsule together with 240 ml tap water and blood sampling at time points blank, 15, 30, 45 min, 1, 2, 3, 4, 6, 8, 10, 12 h of study days 1 and 3 and urine sampling for 24 h at study days 1 and 3
Study: NCT01950819
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects received maintenance therapy with corticosteroids throughout the 24 month study period. A minimum dose of 5 mg prednisone, or equivalent, per day was maintained.
Study: NCT01843010
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 5ml will be intravenously infused.
Study: NCT02633176
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m\^2 orally twice a day, days 1 to 14 of each 21 day cycle for at least 2 years or until progression following concurrent chemoradiation.
Study: NCT01993472
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02122627
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01524380
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice a day, 10 weeks
Study: NCT01309737
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral BID, Continuous treatment for 52 Weeks
Study: NCT01309737
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oral BID, Continuous treatment for 52 Weeks
Study: NCT01309737
Drug: Placebo/CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg oral BID, Continuous Treatment for 16 Weeks; 5 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
Study: NCT00255710
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00961961
Drug: Lithium / Fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized Daily Dosage
Study: NCT02502864
Drug: Standard of Care: Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycle 1: 600 mg/m\^2, via IV on Day 1 for 30 minutes. The cyclophosphamide dose will not be changed unless dictated by toxicity.
Study: NCT02375867
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 1 mg/Kg/day
Study: NCT00525577
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet, once daily
Study: NCT02802631
Drug: Minocin (minocycline) for Injection
Normalized name: minocycline Injection [Minocin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous formulation of minocycline, a derivative of tetracycline
Study: NCT01658514
Drug: Met DR
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin delayed-release tablets
Study: NCT01658514
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01219556
Drug: Olmesartan plus hydrochlorothiazide (Xirtam H, BAY98-7105)
Normalized name: hydrochlorothiazide / olmesartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Xirtam H tablets every 24 hours (Q24H) or as per prescribing information
Study: NCT03437447
Drug: Cisticid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received single oral dose of 1200 mg (two 600 mg tablets) Cisticid (Test) on Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2) or Day 15 (Treatment Period 3).
Study: NCT02154399
Drug: EF5
Normalized name: Hb 76(EF5), Met-thr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT02748967
Drug: ExPEC4V
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant will receive single dose 0.5 ml of ExPEC4V as intramuscular injection on Day 1.